DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-qualified stock options to purchase 150,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment agreement in accordance with Nasdaq Listing rule 5635(c)(4).
The stock option has an exercise price per share equal to $1.00 per share, Chimerix’s closing trading price on November 20, 2023. The stock option has a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of the grant date and the remaining three-fourths vesting over the following three years in equal monthly installments. The stock option is subject to the terms of Chimerix’s 2013 Equity Incentive Plan but was granted outside of the 2013 Equity Incentive Plan.
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.
CONTACTS:
Michelle LaSpaluto
919 972-7115
ir@chimerix.com
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
- Camfil Breaks Down 2025 State of the Air Report with Accessible Explanations and Actionable Insights - June 17, 2025
- The Piano Pod Launches First Live Concert at The New School, Expanding Its Role as a Cultural Connector in Arts and Education - June 17, 2025
- Pioneer Acquisition I Corp Announces Pricing of $220,000,000 Initial Public Offering - June 17, 2025
